Korrekt stadieinndeling er avgjørende fordi den gir viktig prognostisk informasjon og legger grunnlaget for videre behandling. For primære melanom ≥ stadium pT2b (ulcerert melanom med tykkelse 1,1–2,0 mm) eller høyere, vurderes vaktpostlymfeknutebiopsi for å avdekke eventuell metastasering til regionale lymfeknuter. Prosedyren kan vurderes, men sjelden indisert hos pT1b og pT2a. Resultatet av denne prosedyren gir et patologisk N-stadium, som muliggjør eksakt stadieinndeling. Dersom det påvises metastaser i én eller flere lymfeknuter, vil pasienten kunne klassifiseres i stadium IIIA–IIID, avhengig av antall affiserte knuter, metastasens størrelse og eventuelle histopatologiske risikofaktorer.
7. Utredning for stadieinndeling
7. 1. TNM og stadiegrupperinger
7. 2. Bildediagnostikk
7. 3. Melanom multidisiplinært team (MDT)
Balch, C. M., Soong, S. J., Atkins, M. B., Buzaid, A. C., Cascinelli, N., Coit, D. G., Fleming, I. D., Gershenwald, J. E., ... Thompson, J. F. (2004). An evidence-based staging system for cutaneous melanoma. CA: a cancer journal for clinicians, 54(3), 131-49; quiz 182-4.
Bastiaannet, E., Wobbes, T., Hoekstra, O. S., van der Jagt, E. J., Brouwers, A. H., Koelemij, R., de Klerk, J. M., Oyen, W. J., ... Hoekstra, H. J. (2009). Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. Journal of clinical oncology, 27(28), 4774-80.
Bochev, P., Klisarova, A., Kaprelyan, A., Chaushev, B., & Dancheva, Z. (2012). Brain metastases detectability of routine whole body (18)F-FDG PET and low dose CT scanning in 2502 asymptomatic patients with solid extracranial tumors. Hellenic journal of nuclear medicine, 15(2), 125-9.
Brierley, J. D., Gospodarowicz, M. K., Wittekind, C. (2017). TNM classification of malignant tumours. Wiley-Blackwell.
Chai, C. Y., Zager, J. S., Szabunio, M. M., Marzban, S. S., Chau, A., Rossi, R. M., & Sondak, V. K. (2012). Preoperative ultrasound is not useful for identifying nodal metastasis in melanoma patients undergoing sentinel node biopsy: preoperative ultrasound in clinically node-negative melanoma. Annals of surgical oncology, 19(4), 1100-6.
Coit, D. G., Thompson, J. A., Albertini, M. R., Barker, C., Carson, W. E., Contreras, C., Daniels, G. A., DiMaio, D., ... Engh, A. M. (2019). Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 17(4), 367-402.
Edge, S., Byrd, S. R., Compton, C. C., Fritz, A. G., Greene, F. L., Trotti, A. (2010). AJCC Cancer Staging Manual. Springer-Verlag.
Gershenwald, J. E., & Scolyer, R. A. (2018). Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Annals of surgical oncology, 25(8), 2105-2110.
Gold, J. S., Jaques, D. P., Busam, K. J., Brady, M. S., & Coit, D. G. (2007). Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy. Annals of surgical oncology, 14(7), 2133-40.
Goyal, S., Silk, A. W., Tian, S., Mehnert, J., Danish, S., Ranjan, S., & Kaufman, H. L. (2015). Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review. JAMA oncology, 1(5), 668-76.
Holtkamp, L. H. J., Read, R. L., Emmett, L., Thompson, J. F., & Nieweg, O. E. (2017). Futility of imaging to stage melanoma patients with a positive sentinel lymph node. Melanoma research, 27(5), 457-462.
Kesson, E. M., Allardice, G. M., George, W. D., Burns, H. J., & Morrison, D. S. (2012). Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ (Clinical research ed.), 344, e2718.
Keung, E. Z., & Gershenwald, J. E. (2018). The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert review of anticancer therapy, 18(8), 775-784.
Nasjonalt kvalitetsregister for melanom (2021). Årsrapport 2020: resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for melanom Oslo: Kreftregisteret. Hentet fra https://www.kvalitetsregistre.no/sites/default/files/2021-10/%C3%85rsrapport%20Nasjonalt%20kvalitetsregister%20for%20melanom%202020.pdf
Rodriguez Rivera, A. M., Alabbas, H., Ramjaun, A., & Meguerditchian, A. N. (2014). Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis. Surgical oncology, 23(1), 11-6.
Romano, E., Scordo, M., Dusza, S. W., Coit, D. G., & Chapman, P. B. (2010). Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. Journal of clinical oncology, 28(18), 3042-7.
Sainsbury, R., Haward, B., Rider, L., Johnston, C., & Round, C. (1995). Influence of clinician workload and patterns of treatment on survival from breast cancer. Lancet, 345(8960), 1265-70.
Schroer-Gunther, M. A., Wolff, R. F., Westwood, M. E., Scheibler, F. J., Schurmann, C., Baumert, B. G., Sauerland, S., & Kleijnen, J. (2012). F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review. Systematic reviews, 1, 62.
Schule, S. C., Eigentler, T. K., Garbe, C., la Fougere, C., Nikolaou, K., & Pfannenberg, C. (2016). Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. European journal of nuclear medicine and molecular imaging, 43(3), 482-8.
Xing, Y., Bronstein, Y., Ross, M. I., Askew, R. L., Lee, J. E., Gershenwald, J. E., Royal, R., & Cormier, J. N. (2011). Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. Journal of the National Cancer Institute, 103(2), 129-42.
Siste faglige endring: 21. november 2025